Mirza W. Ali

Statistics

Publications

Citations

3.3K

H-Index

Active since

1990

Affiliations

Otsuka (United States)(Current)

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Germany)

Zucker Hillside Hospital

Maryland Medical Research Institute

Mirza W. Ali is an author at Otsuka (United States) specializing in schizophrenia pharmacotherapy, neuropharmacology, and antipsychotic pharmacotherapy.

ORCID

Publications per year

1990–2014

Publications

Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder

John M. Kane, William H. Carson, Anutosh Ranjan Saha et al. · The Journal of Clinical Psychiatry · 2002 · 625 citations

Medicine, Pharmacotherapy, Psychiatry +17

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

Steven G. Potkin, Anutosh Ranjan Saha, Mary J. Kujawa et al. · Archives of General Psychiatry · 2003 · 593 citations

Medicine, Pharmacology, Pharmacotherapy +16

A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania

Paul E. Keck, Ronald N. Marcus, Stavros Tourkodimitris et al. · American Journal of Psychiatry · 2003 · 503 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Stephen R. Marder, Robert D. McQuade, Elyse Stock et al. · Schizophrenia Research · 2003 · 469 citations

Medicine, Pharmacology, Psychiatry +10

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

Siegfried Kasper, Mark N. Lerman, Robert D. McQuade et al. · The International Journal of Neuropsychopharmacology · 2003 · 310 citations

Medicine, Pharmacology, Pharmacotherapy +16

1–5 of 22